Biosimilars facilitate patient access, provide more affordable treatment options and encourage innovation.1,2
Lower cost
The development of biosimilars can create lower patient costs for treatment, which can lead to:
- Increased uptake of best-value biologics1,2
- Reinvestment of cost savings in the development of new and innovative therapies1
- Improved patient care1
- Additional treatment choices for patients and HCPs1
Encouraging innovation
The development of biosimilars can create a more progressive, competitive environment, encouraging investment in the development of new biologic products.1 This can lead to:
- Innovation among reference product manufacturers1
- Increased uptake of best-value biologics1,2
- Reinvestment of cost savings in the development of new and innovative therapies1
What types of biosimilars do we have in development? Learn here
References:
1. IMS Institute 2016. Delivering on the potential of biosimilar medicines. Accessed June 22, 2020 at: www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf.
2. IMS Health 2016. The impact of biosimilar competition. Accessed June 22, 2020 at: www.medicinesforeurope.com/wp-content/uploads/2016/08/IMS-Impact-of-Biosimilar-Competition-2016.pdf.
